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Critically ill patients with respiratory failure from acute respiratory distress syndrome 
(ARDS) have reduced ability to clear alveolar edema fluid. This reduction in alveolar fluid 
clearance (AFC) contributes to the morbidity and mortality in ARDS. Thus, it is important 
to understand why AFC is reduced in ARDS in order to design targeted therapies. In 
this review, we highlight experiments that have advanced our understanding of ARDS 
pathogenesis, with particular reference to the alveolar epithelium. First, we review how 
vectorial ion transport drives the clearance of alveolar edema fluid in the uninjured lung. 
Next, we describe how alveolar edema fluid is less effectively cleared in lungs affected by 
ARDS and describe selected in vitro and in vivo experiments that have elucidated some 
of the molecular mechanisms responsible for the reduced AFC. Finally, we describe one 
potential therapy that targets this pathway: bone marrow-derived mesenchymal stem 
(stromal) cells (MSCs). Based on preclinical studies, MSCs enhance AFC and promote 
the resolution of pulmonary edema and thus may offer a promising cell-based therapy 
for ARDS.
Keywords: acute respiratory distress syndrome, alveolar fluid clearance, mesenchymal stem (stromal) cells, 
pulmonary edema, vectorial ion transport
inTRODUCTiOn
Pulmonary edema is the abnormal accumulation of fluid in the interstitium and air spaces of the 
lungs, which leads to impaired gas exchange and respiratory failure. Pulmonary edema can develop 
from increased pulmonary vascular pressure from left heart failure (cardiogenic pulmonary edema) 
(1) or from lung parenchymal damage from increased endothelial and epithelial permeability (non-
cardiogenic pulmonary edema) (2). In both cases, the mechanism for the resolution of alveolar 
edema is the same: active ion transport across the alveolar epithelium creates an osmotic gradient 
that drives alveolar fluid clearance (AFC) (3). In the presence of acute lung endothelial and epithelial 
injury, there is complexity in describing the forces responsible for lung fluid clearance, meaning 
removal of edema from the lung itself. Net AFC does depend on an intact epithelial barrier that 
can transport ions from the apical to the basolateral surface and create a mini-osmotic gradient 
for alveolar fluid absorption. If transvascular fluid flux is increased across lung endothelium from 
increased pressure or increased permeability, then the rate of AFC will be reduced. Also, net lung 
fluid clearance will be less. Lung lymphatics do remove edema fluid in either hydrostatic or increased 
FigURe 1 | Alveolar fluid clearance pathways. Shown are the interstitial, 
capillary, and alveolar compartments, with pulmonary edema fluid in the 
alveolus. Both type I (yellow) and type II (orange) alveolar cells are involved in 
transepithelial ion transport. Sodium (Na+) is transported across the apical 
side of the type I and type II cells through the epithelial sodium channel 
(ENaC), and then across the basolateral side via the sodium/potassium 
ATPase pump (Na/K-ATPase). Chloride (Cl−) is transported via the cystic 
fibrosis transmembrane conductance regulator (CFTR) channel or by a 
paracellular route. Additional cation channels also transport ions across the 
alveolar epithelium (not shown). This vectorial ion transport creates an 
osmotic gradient that drives the clearance of fluid. Specifically, water (H2O) 
moves down the osmotic gradient through aquaporin channels, such as 
aquaporin 5 (AQP5) or via an intracellular route (not shown).
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permeability lung edema, but they cannot entirely compensate 
for an increase in transvascular fluid flux or impaired AFC.
Acute respiratory distress syndrome (ARDS) is a syndrome of 
acute respiratory failure caused by non-cardiogenic pulmonary 
edema. The most common cause of ARDS is bacterial or viral 
pneumonia (4). Sepsis due to non-pulmonary sources, trauma, 
aspiration, pancreatitis, transfusion reactions, and drug reactions 
can also lead to ARDS (4). Criteria for the diagnosis of ARDS 
have changed over time, but the current definition includes arte-
rial hypoxemia with PaO2/FiO2 ratio less than 300 mmHg, bilat-
eral radiographic opacities, without evidence of that is not fully 
explained by cardiac failure or fluid overload (5). The mortality 
of ARDS is approximately 25–40% (6), and treatment remains 
primarily supportive with lung protective ventilation and a fluid 
conservative strategy (7).
Because ARDS has a broad clinical phenotype, it has been 
challenging to translate cell and animal studies to pharmaco-
logic therapies that reduce human morbidity and mortality. 
Nonetheless, in vitro and in vivo studies have produced important 
insights about the pathogenesis of this condition, paving the way 
for targeted therapeutics. This review will focus on: (1) mecha-
nisms that mediate the clearance of pulmonary edema in the 
uninjured lung, (2) why AFC is reduced in ARDS, resulting in the 
accumulation of pulmonary edema fluid, and (3) one potential 
treatment for ARDS with a cell-based therapy that may accelerate 
the rate of AFC.
PULMOnARY eDeMA FLUiD CLeARAnCe 
in THe UninJUReD LUng
Before discussing AFC in ARDS, it is first important to review 
how pulmonary edema fluid is cleared in the uninjured lung. In 
the uninjured lung, vectorial ion transport across the alveolar 
epithelial cells creates an osmotic gradient that drives fluid 
from the airspaces into the lung interstitum (Figure 1). It was 
initially thought that alveolar epithelial type II cells were the 
primary cell responsible for vectorial ion transport, but subse-
quent studies demonstrated an important role for type I cells 
as well (8). The transport of sodium ions is the most important 
driver for the generation of the osmotic gradient: sodium is 
transported through the sodium channel (ENaC) on the api-
cal surface and then by the Na/K ATPase on the basolateral 
surface into the lung microcirculation (9, 10). Knockout of 
the alpha-subunit of ENaC in mice resulted in the inability to 
remove lung fluid at birth with subsequent respiratory failure 
and death (9). In addition, non-selective cation channels, cyclic 
nucleotide-gated channels, and the cystic fibrosis transmem-
brane conductance regulator chloride channel also contribute 
to the creation of the osmotic gradient (3, 11). Aquaporins 
facilitate the movement of water across the epithelial surface, 
but are not required for fluid transport (12).
This system of active ion-driven alveolar fluid reabsorption 
is the primary mechanism that removes alveolar edema fluid 
under both physiologic and pathological conditions (9, 13, 
14). However, in the setting of ARDS, the capacity to remove 
alveolar edema fluid is reduced, which is termed impaired AFC. 
A reduction in the rate of AFC in ARDS correlates with decreased 
survival (15, 16). Therefore, it is critical to better understand why 
AFC is reduced in ARDS to better understand the pathogenesis 
of this condition.
PULMOnARY eDeMA FLUiD CLeARAnCe 
in ARDS
Multiple mechanisms explain why AFC is reduced in ARDS. First, 
both hypoxia and hypercapnia impair AFC. ENaC transcription 
and trafficking is downregulated and Na/K-ATPase functions less 
efficiently under states of low oxygen or high carbon dioxide, in 
part, because reactive oxygen species trigger endocytosis and cell 
necrosis (17–19). Therefore, supplemental oxygen and correction 
of hypercapnia can enhance the resolution of alveolar edema (17).
Second, biomechanical stress can reduce AFC. High tidal vol-
umes and elevated airway pressures injure the alveolar epithelium, 
inducing cell death and inflammation, which reduces AFC (20). 
If pulmonary hydrostatic pressures are elevated, the rate of AFC 
is also reduced. These findings help explain the success of lung 
protective ventilation strategies and conservative fluid strategies 
in reducing the morbidity and mortality of ARDS (21, 22).
Third, ARDS pulmonary edema fluid contains high levels of 
pro-inflammatory cytokines including IL-1β, IL-8, TNFα, and 
TGFβ1 (23–25). Under controlled conditions, this inflammatory 
response is important for pathogen clearance. However, when 
excessive levels of cytokines are present, they instead can cause 
FigURe 2 | In vitro model of polarized human alveolar type ii epithelial 
cells. In 2006, Fang et al. developed an in vitro model of the polarized 
human alveolar epithelial surface, which has been used in multiple 
subsequent studies of alveolar fluid clearance (AFC) (32). To create this 
model, type II alveolar epithelial cells are isolated from human donor lungs 
and cultured on a collagen-I coated 24-well plate where they formed tight 
monolayers. Pulmonary edema fluid (pink), which contains water (H2O), 
sodium ions (Na+), chloride ions (Cl−), as well as other ions and proteins, is 
mixed with 131I-albumin (yellow circles) and introduced to the apical 
compartment. Pulmonary edema fluid is able to cross the alveolar cell 
monolayer, but 131I-albumin cannot cross, so it is possible to calculate AFC by 
measuring the change in 131I-albumin concentration between the apical and 
basal compartments.
3
Huppert and Matthay Resolution of Pulmonary Edema
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 371
alveolar injury and decreased AFC (26–29). Moreover, once 
the epithelial barrier is breeched and alveolar fluid is released, 
components of the alveolar fluid may be recognized to induce 
downstream inflammatory and immune responses (30). There 
are no current therapies that directly target this pathway in the 
treatment of ARDS, although lung protective ventilation itself 
reduces pro-inflammatory cytokines such as IL-6 and IL-8 (4, 
31). The remainder of this review will summarize our current 
understanding of alveolar ion transport in ARDS based on 
pathologically relevant in vitro and in vivo models, and discuss 
one potential new therapy that targets this pathway.
In 2006, Fang et al. developed a model of a polarized human 
alveolar type II cell that facilitated in vitro studies of AFC (32) 
(Figure 2). Using this model, Lee et al. found that transepithelial 
fluid transport is less effective in the presence of ARDS edema 
fluid and found that there are increased levels of cytokines and 
decreased levels of ion transport proteins in the presence of 
ARDS edema fluid compared to a plasma control (33). These 
data support the hypothesis that cytokine expression is increased 
in alveolar epithelium during ARDS, resulting in a decreased 
expression of alveolar ion channels and accumulation of alveolar 
edema fluid. In addition, the inflammatory edema fluid can 
also cause alveolar cell injury and necrosis, resulting in altered 
epithelial tight junctions (34, 35). The loss of tight junctions can 
negate the osmotic gradient, offsetting the effects of vectorial ion 
transport.
Subsequent in  vivo studies expanded upon these findings 
and demonstrated that net AFC was reduced under clinically 
relevant pathologic conditions in animal models. In sheep, live 
Pseudomonas aeruginosa decreased AFC at both 4 and 24 h, an 
effect, which was associated with decreased AFC (36). In a mouse 
model of influenza pneumonia, the authors demonstrated that 
there was decreased AFC due to inhibition of the ENaC epithelial 
sodium channel (37). These and other studies confirmed that AFC 
is reduced in lung injury through decreased efficiency of alveolar 
ion channels as well as altered permeability of the normally tight 
alveolar epithelium.
MeSenCHYMAL STeM (STROMAL) CeLLS 
(MSCs) AS A PROMiSing THeRAPY FOR 
ARDS
The laboratory-based investigations described above significantly 
advanced our understanding of ARDS pathophysiology, paving 
the way for targeted molecular therapies to improve the clinical 
treatment of patients with ARDS. MSCs are one such promising 
new cell-based therapy, which we will discuss in this section.
Mesenchymal stem (stromal) cells are bone marrow-derived 
cells that can differentiate in  vitro into chondrocytes, osteo-
blasts, and adipocytes, although they do not have true stem cell 
properties in vivo (38). MSCs secrete paracrine factors that can 
decrease inflammation and enhance endothelial and epithelial 
repair (39). Several groups are studying the therapeutic potential 
of MSCs in sepsis (40, 41), diabetes (42), myocardial infarction 
(43), hepatic failure (44), and acute renal failure (45, 46). It was 
hypothesized that MSCs might also be beneficial in the treat-
ment of ARDS.
To test this hypothesis, several groups studied whether MSCs 
could reduce the severity of lung, kidney, and brain injury in pre-
clinical models (47). In 2007, Gupta et al. reported that treatment 
with MSCs improved survival and reduced pulmonary edema 
in Escherichia coli endotoxin-induced lung injury in mice (48). 
Subsequent studies showed that MSCs attenuated lung injury in 
mice and in ex vivo human lungs injured with live bacteria (49, 
50). MSCs also enhance bacterial clearance and improve survival 
in mouse and rat models of sepsis (41, 51), and they have ben-
eficial effects in ventilator-induced acute lung injury (52). Based 
on this preclinical data, phase 1 and 2 clinical trials are currently 
testing MSCs as a therapy for ARDS (53).
Given the potential therapeutic benefit of MSCs in the treat-
ment of ARDS, it is important to understand their mechanism 
of action and several possible mechanisms have been implicated 
to date. In 2010, Fang et al. used SiRNA knockdown of paracrine 
soluble factors in the setting of MSC treatment in vitro in cul-
tured human type 2 cells and found that angiopoietin-1 secretion 
was partially responsible for the beneficial effect of MSCs (54). 
Subsequent studies suggested that interleukin-1 receptor antago-
nist and growth factors such as keratinocyte growth (KGF) factor 
may also be involved in this process (52). KGF can upregulate 
AFC in ex vivo human lungs injured by endotoxin (55). A 2015 
study demonstrated that lipoxin A4, a pro-resolving lipid media-
tor, is upregulated in the presence of MSCs, suggesting that this 
molecule may be important for MSC-mediated resolution of lung 
injury (56). Other studies indicated that the therapeutic effects 
of MSCs may also mediate the release of microvesicles, which 
are involved in cell–cell communication (57) or due to mito-
chondrial transfer (58). Thus, several mechanisms may explain 
MSC-mediated resolution of lung injury, and further studies are 
needed to fully characterize this process.
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DiSCUSSiOn
The importance of alveolar ion transport in AFC has been 
established, but further work is needed to better characterize 
this process. For example, type I alveolar cells participate in api-
cal–basolateral fluid transport (8, 59), but there is no suitable cell 
culture model for type I cells so the physiology of these cells is not 
as well understood. In addition, sodium transport has been well 
characterized, but the contribution of transport of other ions is 
not as clear. Future experiments are needed to clarify the role of 
type I versus type II alveolar cells and the roles of additional ion 
channels in alveolar fluid transport.
The in vitro and in vivo models of ARDS have enhanced our 
understanding of ARDS pathophysiology. Not only are these 
models useful for the study of ARDS but measurements of AFC 
and paracellular permeability can also be used to better under-
stand other pulmonary conditions. For example, Chan et  al. 
(60) compared the extent to which avian influenza A (H5N1) 
virus and seasonal influenza A (H1N1) virus impair AFC and 
protein permeability using the transwell model first used in the 
ARDS models (60). The authors found that avian influenza A 
(H5N1) virus causes a more severe reduction in alveolar protein 
transport than the seasonal influenza A (H1N1) virus, mimick-
ing its greater clinical severity. Future work can use these models 
to better understand how AFC is affected in other pulmonary 
pathologies as well.
Preliminary preclinical experiments have suggested that MSCs 
promote the resolution of alveolar edema fluid. It is possible that 
MSCs act directly on alveolar ion channels via cell–cell interac-
tions or indirectly via paracrine factors; future experiments are 
needed to clarify their mechanism of action in the lung. If MSCs 
indeed promote AFC, they may serve as a promising cell-based 
therapy for ARDS.
SUMMARY
In this review, we have discussed how vectorial ion channels 
in alveolar epithelium generate an osmotic gradient that drives 
AFC in both physiologic and pathologic conditions. Both AFC 
and paracellular permeability can be measured using in vitro and 
in vivo models of ARDS, and these studies indicate that vectorial 
ion transport is less effective in injured lungs than in uninjured 
lungs. Recent studies suggest that MSCs interact with alveolar 
epithelium and ion channels to increase AFC and thus may serve 
as a promising treatment for ARDS.
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